Interestingly, in addition, PARP inhibitors have recently been proposed as HDT compounds for reducing TB-induced inflammation (14), thereby providing a potential mechanistic link between the TB-DM co-morbidity at the molecular level. Here, PARP1 is linked to diabetes mellitus.